WHAT IS CANNABIGEROL MONOETHYLETHER (CBGM)?
Cannabigerol (CBG), also known as CBG, is a group of cannabinoids found in the cannabis or marijuana plant. Unlike other cannabinoids, like THC, CBG and its derivatives does not get one high when consumed.
Instead, it is reported that CBG blocks the psychoactive effect of THC while still providing the body with medicinal benefits. Part of the CBG group is the cannabinoid cannabigerol monomethyl ether (CBGM).
CBGM was discovered in 1968 by scientists from Kyushu University in Japan. The compound was discovered from a Japanese cannabis strain called Minamioshihara No. 1.
When the scientists were using acid to separate compounds from the cannabis plant, they discovered a pale-yellow colored syrup-like substance which was later called CBGM.
They were also able to derive the compound through the process of methylation; this involves the process of adding methyl molecules. CBGM is one of the two cannabinoids in the CBG group that is ether.
At this time, many of the cannabinoids are still undergoing research. Though little is known about this compound (CBGM), the limited knowledge available about it is derived from CBG.
There is hope that more research on CBGM will help to fully understand the compound and its effects.
HOW DOES CBGM WORK?
Apart from the molecular structure, researchers are yet to know what makes CBGM different from the CBG group.
There are possibilities that the compound might affect the body the same way other cannabinoids under CBG does. However, but since CBGM is an ether compound, this could cause it to affect the body in a way different from other cannabinoids.
But generally, CBGs are said to interact with the body by impacting the Endocannabinoid System (ECS) of the body.
Endocannabinoids are naturally produced cannabinoids by the body that are responsible for the regulation of physiological functions and maintenance of internal balance.
POSSIBLE THERAPEUTIC BENEFITS
To fully understand the therapeutic effects of CBGM, more research has to be done. One can only speculate that since CBGM is a member of the CBGs, it may provide the same medicinal benefits as other CBGs.
If CBGM imitates the therapeutic effects of CGB, then it has potential in helping patients with the following conditions;
There are reports that CBG can treat glaucoma by reducing the painful intraocular eye pressure.
Although the study has only been done on study rats, scientists are confidents that the compound might have the same effects if used on humans.
It was reported that CBG showed excellent anti-inflammatory effects than CBD. The study was done on lab rats with inflammatory Bowel Diseases; ulcerative colitis and Crohn’s disease, and they benefitted from the compounds’ anti-inflammatory therapeutic benefit.
CBG is also reported to have anti-cancer and analgesic benefits. It is also capable of reducing nausea.
Another study done on rat models showed that CBG is capable of treating neurodegenerative diseases like Huntington’s diseases.
COLASANTI, B. K. (1990). A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol. Journal of Ocular Pharmacology and Therapeutics, 6(4), 259–269.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., … Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), 1306–1316
Banerjee SP, Snyder SH, Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J Pharmacol Exp Ther. 1975;194(1):74-81.] than THC.